| Gregory J Griepentrog, MD | |
|
925 N 87th St, Medical College Clinics At The Eye Institute, Milwaukee, WI 53226-4812 | |
| (414) 456-2020 | |
| (414) 456-6300 |
| Full Name | Gregory J Griepentrog |
|---|---|
| Gender | Male |
| Speciality | Ophthalmology |
| Experience | 20 Years |
| Location | 925 N 87th St, Milwaukee, Wisconsin |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1114991890 | NPI | - | NPPES |
| 1114991890 | Medicaid | WI | |
| 60983 | Other | WI | DEAN HEALTH INSURANCE |
| 548332800 | Medicaid | MN |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207W00000X | Ophthalmology | 52797-020 (Wisconsin) | Secondary |
| 207WX0200X | Ophthalmology - Ophthalmic Plastic And Reconstructive Surgery | 52797 (Wisconsin) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Froedtert Memorial Lutheran Hospital | Milwaukee, WI | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| The Medical College Of Wisconsin Inc | 2668384371 | 1813 |
| Froedtert Andthe Medical College Of Wisconsin Community Physicians Inc | 3678760063 | 1040 |
News Archive
The Zika virus may be associated with an autoimmune disorder that attacks the brain's myelin similar to multiple sclerosis, according to a small study that is being released today and will be presented at the American Academy of Neurology's 68th Annual Meeting in Vancouver, Canada, April 15 to 21, 2016.
Regulus Therapeutics Inc. announced today that the Company has received a $10 million equity investment from sanofi-aventis in connection with the landmark alliance the two companies entered into on June 21, 2010. The equity investment by sanofi-aventis further strengthens the balance sheet of Regulus, and with this investment sanofi-aventis becomes the third investor in Regulus, along with its founding companies Alnylam Pharmaceuticals, Inc. and Isis Pharmaceuticals, Inc..
A new web and app-based software solution, launched in the UK today on World MS Day, will allow physicians and nurses to monitor treatment of patients taking MS disease-modifying treatment Rebif by collecting injection history through the new RebiSmart 2.0 electronic autoinjector.
Responding to weeks of criticism over his administration's COVID-19 response, President Donald Trump claimed at a White House briefing that the United States has well surpassed other countries in testing people for the virus.
Non-small cell lung cancer (NSCLC) is one of the leading causes of cancer deaths worldwide. Current therapies that target cellular kinases have been effective for some patients: however, many individuals with NSCLS do not respond.
› Verified 5 days ago
| Entity Name | The Medical College Of Wisconsin Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1699720086 PECOS PAC ID: 2668384371 Enrollment ID: O20031120000259 |
News Archive
The Zika virus may be associated with an autoimmune disorder that attacks the brain's myelin similar to multiple sclerosis, according to a small study that is being released today and will be presented at the American Academy of Neurology's 68th Annual Meeting in Vancouver, Canada, April 15 to 21, 2016.
Regulus Therapeutics Inc. announced today that the Company has received a $10 million equity investment from sanofi-aventis in connection with the landmark alliance the two companies entered into on June 21, 2010. The equity investment by sanofi-aventis further strengthens the balance sheet of Regulus, and with this investment sanofi-aventis becomes the third investor in Regulus, along with its founding companies Alnylam Pharmaceuticals, Inc. and Isis Pharmaceuticals, Inc..
A new web and app-based software solution, launched in the UK today on World MS Day, will allow physicians and nurses to monitor treatment of patients taking MS disease-modifying treatment Rebif by collecting injection history through the new RebiSmart 2.0 electronic autoinjector.
Responding to weeks of criticism over his administration's COVID-19 response, President Donald Trump claimed at a White House briefing that the United States has well surpassed other countries in testing people for the virus.
Non-small cell lung cancer (NSCLC) is one of the leading causes of cancer deaths worldwide. Current therapies that target cellular kinases have been effective for some patients: however, many individuals with NSCLS do not respond.
› Verified 5 days ago
| Entity Name | Froedtert &the Medical College Of Wisconsin Community Physicians Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1568787448 PECOS PAC ID: 3678760063 Enrollment ID: O20101210000699 |
News Archive
The Zika virus may be associated with an autoimmune disorder that attacks the brain's myelin similar to multiple sclerosis, according to a small study that is being released today and will be presented at the American Academy of Neurology's 68th Annual Meeting in Vancouver, Canada, April 15 to 21, 2016.
Regulus Therapeutics Inc. announced today that the Company has received a $10 million equity investment from sanofi-aventis in connection with the landmark alliance the two companies entered into on June 21, 2010. The equity investment by sanofi-aventis further strengthens the balance sheet of Regulus, and with this investment sanofi-aventis becomes the third investor in Regulus, along with its founding companies Alnylam Pharmaceuticals, Inc. and Isis Pharmaceuticals, Inc..
A new web and app-based software solution, launched in the UK today on World MS Day, will allow physicians and nurses to monitor treatment of patients taking MS disease-modifying treatment Rebif by collecting injection history through the new RebiSmart 2.0 electronic autoinjector.
Responding to weeks of criticism over his administration's COVID-19 response, President Donald Trump claimed at a White House briefing that the United States has well surpassed other countries in testing people for the virus.
Non-small cell lung cancer (NSCLC) is one of the leading causes of cancer deaths worldwide. Current therapies that target cellular kinases have been effective for some patients: however, many individuals with NSCLS do not respond.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Gregory J Griepentrog, MD 925 N 87th St, Medical College Clinics At The Eye Institute, Milwaukee, WI 53226-4812 Ph: (414) 456-2020 | Gregory J Griepentrog, MD 925 N 87th St, Medical College Clinics At The Eye Institute, Milwaukee, WI 53226-4812 Ph: (414) 456-2020 |
News Archive
The Zika virus may be associated with an autoimmune disorder that attacks the brain's myelin similar to multiple sclerosis, according to a small study that is being released today and will be presented at the American Academy of Neurology's 68th Annual Meeting in Vancouver, Canada, April 15 to 21, 2016.
Regulus Therapeutics Inc. announced today that the Company has received a $10 million equity investment from sanofi-aventis in connection with the landmark alliance the two companies entered into on June 21, 2010. The equity investment by sanofi-aventis further strengthens the balance sheet of Regulus, and with this investment sanofi-aventis becomes the third investor in Regulus, along with its founding companies Alnylam Pharmaceuticals, Inc. and Isis Pharmaceuticals, Inc..
A new web and app-based software solution, launched in the UK today on World MS Day, will allow physicians and nurses to monitor treatment of patients taking MS disease-modifying treatment Rebif by collecting injection history through the new RebiSmart 2.0 electronic autoinjector.
Responding to weeks of criticism over his administration's COVID-19 response, President Donald Trump claimed at a White House briefing that the United States has well surpassed other countries in testing people for the virus.
Non-small cell lung cancer (NSCLC) is one of the leading causes of cancer deaths worldwide. Current therapies that target cellular kinases have been effective for some patients: however, many individuals with NSCLS do not respond.
› Verified 5 days ago
Lincoln Shaw, Ophthalmology Medicare: Medicare Enrolled Practice Location: 2600 N Mayfair Rd Ste 901, Milwaukee, WI 53226 Phone: 773-702-3937 | |
Jay A. Met, MD Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 2600 N Mayfair Rd, #350, Milwaukee, WI 53226 Phone: 414-777-0110 | |
Jane Marie Collis-geers, M.D. Ophthalmology Medicare: Medicare Enrolled Practice Location: 2906 S 20th St, Milwaukee, WI 53215 Phone: 414-672-1353 Fax: 414-385-7552 | |
Jacquelyn Laplant, Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 925 N 87th St, Milwaukee, WI 53226 Phone: 414-955-2020 Fax: 414-955-6300 | |
Shivam Vipul Amin, MD Ophthalmology Medicare: Medicare Enrolled Practice Location: 925 N 87th St, Milwaukee, WI 53226 Phone: 414-955-2020 Fax: 414-955-6300 | |
Meisha Raven, D.O. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 2900 W Oklahoma Ave, Milwaukee, WI 53215 Phone: 414-649-3323 | |
Dr. Jane Kivlin, MD Ophthalmology Medicare: Not Enrolled in Medicare Practice Location: 9000 West Wisconsin Avenue, Children's Hospital Of Wisconsin, Milwaukee, WI 53226 Phone: 414-805-3666 |